MediWound Ltd. MDWD

MDWD Company Overview

MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing enzymatic therapies for tissue repair and wound care. The company operates primarily in the biotechnology and advanced therapeutics industries, with a concentration on severe burn treatment, chronic wound management, and biologics-based debridement technologies. Its core commercial product is NexoBrid, a bromelain-based biologic therapy designed for eschar removal in severe thermal burns. The company is also advancing EscharEx for chronic wounds and MW005 for non-invasive treatment applications in dermatology and aesthetic medicine.

The company generates revenue through product sales, licensing agreements, government-supported development programs, and strategic collaborations. MediWound’s customer base includes hospitals, burn centers, military and emergency preparedness organizations, and healthcare systems in multiple international markets. A key strategic differentiator is its proprietary bromelain-derived enzymatic platform, which enables selective tissue debridement while potentially reducing surgical intervention requirements. Founded in Israel in 2000, MediWound evolved from an early-stage biotechnology developer into a publicly traded company listed on Nasdaq under the ticker MDWD, with expanded regulatory approvals and international commercialization partnerships over time.